Eloxatin
Islet Cell Carcinoma
Alliance for Clinical Trials in OncologyPhase 2/3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Islet Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Octreotide Pamoate RayzeBio, Inc. | Phase 3 | BB |
Capecitabine Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | BB |
FILGRASTIM Roswell Park Cancer Institute | Phase 2 | B |
Catequentinib | Phase 2 | CCC |
ptk787 | Phase 2 | CCC |
Antineoplaston A10 | Phase 2 | CC |
Antineoplaston As2-1 | Phase 2 | CC |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →